A separate analysis from the same trial
Ryan and colleagues examined long-term weight outcomes in SELECT’s 17,604 adults with cardiovascular disease and overweight or obesity, without diabetes. The 2024 paper is distinct from the trial’s primary cardiovascular report. Average weight loss at 208 weeks was 10.2% with semaglutide and 1.5% with placebo in the in-trial analysis.
Who remains in the calculation matters
The on-treatment analysis showed a larger average reduction with semaglutide, 11.7%. In-trial and on-treatment results address different analysis populations. The authors also reported more treatment discontinuations with semaglutide. These details matter when interpreting a phrase such as “sustained for four years.”
An average is not an individual forecast
Think of a class average: it summarizes a group without saying that every student received that mark. A long-term weight average should be read with the same care. Ask about the spread of outcomes, the people represented late in follow-up and how missing observations were handled. A single endpoint cannot describe every participant’s path.
Observation time cannot create a missing comparison
If the question is whether planned interruptions improve outcomes, the study must compare suitable interruption strategies. Adding more years to another design does not answer that question automatically. Likewise, four years of observation should not be translated into a lifetime guarantee or an individual instruction to continue, stop or restart anything.
What readers can carry forward
The complete publisher PDF was reviewed, including methods and limitations. The selected population limits generalization; the trial was funded by Novo Nordisk. Use this article to check what a long-term claim actually measures. It provides no generic cycle, treatment schedule or assurance about commercial research material.